Genetically Targeted
Designed to reduce craving to effectively curb alcohol intake in those patients with the genetics expected to indicate a likely response to treatment with AD04
BRINGS 20+ YEAR TRACK RECORD OF CLINICAL USE
To date, clinical testing of AD04 has shown it to have a positive safety and tolerability profile with side effects similar to placebo.
Oral daily dosing
Our product candidate is intended to be easy to use since it is administered orally.
Media
AUD is characterized by an urge to consume alcohol and an inability to control the levels of consumption
Email Alerts
SIGN UP TODAYLatest Tweets
Adial Pharmaceuticals expands addiction medication drug research into opioids
Charlottesville pharma company looks to combat opioid addiction
Charlottesville-based Adial Pharmaceuticals plans to expand an under-development drug to treat alcoholism to target opioids.
goo.gl
Adial Pharmaceuticals (NASDAQ: ADIL) Announces Amendment to License Agreement with the @UVALVG : https://t.co/IpAdcCEaX9
#clinicaltrials #drugdevelopment #addictionrecovery #UVa #Pharmaceuticals #nasdaq #adil #medicine #pharma18
Here as an example as to why our expansion of AD04 into opioid addiction, including #fentanyl, is necessary. Learn More https://t.co/xKmY6amaWX
Adial Pharmaceuticals Announces Planned Expansion of Lead Asset AD04 into Opioid Addiction Including Synthetic Opioids Such as Fentanyl
goo.gl
Fentanyl has surpassed heroin as the drug most frequently involved in overdose deaths in the U.S., according to a new CDC report. https://t.co/kuE6Cxve2k
AD04 Ready to Enter Phase 3 in Targeted Groups
Adial is preparing to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes.
Adial has created an investigational attendant diagnostic biomarker blood test for the genetic screening of patients with certain biomarkers that, as reported in the American Journal of Psychiatry (Johnson, et. al. 2011 & 2013), Adial believes make patients more likely to benefit from treatment with AD04.
Adial’s strategy is to integrate pre-treatment genetic screening into AD04’s label to create a patient-specific treatment in one integrated therapeutic offering. Adial’s goal is to develop a genetically targeted, effective and safe product candidate to treat AUD that does not require abstinence as part of the treatment.